Analytical Data
-
Gene name
GRINL1A
- Application
-
Alternative Names
MYZAP; MYOZAP; Myocardial zonula adherens protein; GRINL1A upstream protein; Gup
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P0CAP1
-
Expression Region
1-368aa
-
AA Sequence
MCSLPRGFEPQAPEDLAQRSLVELREMLKRQERLLRNEKFICKLPDKGKKIFDSFAKLKAAIAECEEVRRKSELFNPVSLDCKLRQKAIAEVDVGTDKAQNSDPILDTSSLVPGCSSVDNIKSSQTSQNQGLGRPTLEGDEETSEVEYTVNKGPASSNRDRVPPSSEASEHHPRHRVSSQAEDTSSSFDNLFIDRLQRITIADQGEQQSEENASTKNLTGLSSGTEKKPHYMEVLEMRAKNPVPQLRKFKTNVLPFRQNDSSSHCQKSGSPISSEERRRRDKQHLDDITAARLLPLHHMPTQLLSIEESLALQKQQKQNYEEMQAKLAAQKLAERLNIKMRSYNPEGESSGRYREVRDEDDDWSSDEF
-
Molecular Weight
68.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GRINL1A, a member of the glutamate receptor ion channel family, has garnered significant attention in recent years due to its potential implications in neurodevelopmental and psychiatric disorders. As a repressor of glutamate signaling, GRINL1A is believed to play a critical role in synaptic plasticity and neuronal communication. Research has shown that aberrations in glutamate signaling pathways are linked to conditions such as schizophrenia, autism, and epilepsy, making GRINL1A a compelling target for therapeutic interventions. The study of GRINL1A recombinant proteins enables researchers to delve deeper into its structural and functional characteristics, providing insights into how it regulates glutamate receptor activity. By producing and characterizing this protein in vitro, scientists can explore its binding interactions, post-translational modifications, and impact on neuronal excitability. Furthermore, understanding GRINL1A's role in various signaling pathways could illuminate its contribution to developmental processes in the brain. This knowledge is essential for the development of targeted therapies aimed at restoring normal glutamate signaling in affected individuals, thus highlighting the importance of GRINL1A in both basic neuroscience research and potential clinical applications.
